Valneva Announces Positive Phase 2 Results for Chikungunya Vaccine in Children

Valneva SE has released positive final results from its Phase 2 trial of the chikungunya vaccine, IXCHIQ®, in children aged one to eleven. The vaccine demonstrated strong antibody persistence and safety. The trial included 304 children and showed that the full dose elicited a more robust immune response 12 months post-vaccination compared to the half dose. Notably, the vaccine was well tolerated, irrespective of prior chikungunya infection.

This study, partially funded by CEPI and supported by the European Union, provides a basis for selecting the full dose for forthcoming Phase 3 trials. The continued investigation in adolescent populations will aid in refining the approach for Phase 3 trials in children.